Brief: Aprinoia Therapeutics & Ross Acquisition Corp II Announce Business Combination Agreement

Ross Acquisition II

18/01/2023 13:43

Jan 18 (Reuters) - Ross Acquisition II Corp  ROSS.N :
    * APRINOIA THERAPEUTICS AND ROSS ACQUISITION CORP II
ANNOUNCE
BUSINESS COMBINATION AGREEMENT TO CREATE PUBLICLY LISTED COMPANY
FOCUSED ON NEURODEGENERATIVE DISEASES
    * ROSS ACQUISITION II CORP - ROSS SPAC WILL ISSUE $280
MILLION OF
STOCK FOR APRINOIA THERAPEUTICS
    * ROSS ACQUISITION II CORP - COMBINED COMPANY IS EXPECTED TO
BE
TRADED ON NASDAQ OR NYSE UPON CLOSING
    * ROSS ACQUISITION II CORP - COMBINED COMPANY IS EXPECTED TO
BE
TRADED ON NASDAQ OR NYSE UPON CLOSING
    * ROSS ACQUISITION II CORP - ANTICIPATED PROCEEDS FROM DEAL
EXPECTED TO FINANCE SEVERAL KEY THERAPEUTIC AND DIAGNOSTIC
PROGRAMS TO DATA ANNOUNCEMENTS
    * ROSS ACQUISITION II CORP - ROSS AND APRINOIA ARE COMBINING
AT AN
IMPLIED FULLY DILUTED TRANSACTION EQUITY VALUE OF US$280 MILLION
FOR APRINOIA
    * ROSS ACQUISITION II CORP - BUSINESS COMBINATION VALUES
POST-CLOSING COMBINED BUSINESS AT A PRO FORMA ENTERPRISE VALUE
OF UP TO US$319.6 MILLION

Source text for Eikon:  ID:nPn2ThHmNa 
Further company coverage:  ROSS.N 
 ((Reuters.Briefs@thomsonreuters.com;))